摘要
在寻求改进心脏疾病表型建模方法和准确筛选潜在治疗化合物的药效和毒性的方法中,人诱导多能干细胞成为促进药物开发和改善疾病建模能力的一个重要工具。它们源自体细胞,又具有增殖分化能力,使其能够开发成个性化的医疗策略和特异性的疾病模型。目前基于人诱导多能干细胞分化的心肌细胞的体外疾病模型已用于药物发现与验证、有效性及安全性评价,对未知的疾病机制的阐明,为开展临床试验奠定了基础。本文主要概述了基于人诱导多能干细胞分化的心肌细胞作为心脏疾病模型的研究进展及其在药物筛选中的应用。
Human-induced pluripotent stem cells(hiPSCs)have become an important tool for promoting disease modeling and drug development in the search for ways to improve phenotypic modeling of heart disease and accurately screen the efficacy and toxicity of potentially therapeutic compounds.And hiPSCs are derived from somatic cells and have the ability of differentiation and proliferation that make them possible to develop personalized medical strategies and disease-specific models.Currently,the in vitro disease models based on cardiomyocytes derived from hiPSCs have been used for drug discovery and validation,efficacy and safety evaluation,elucidation of the unknown mechanism of disease,which provide the basis to conduct clinical trials.The progress of cardiomyocytes derived from hiPSCs as cardiac disease models and their applications to drug screening is summarized in this paper.
作者
邢红艳
张艺哲
王美婷
赵琪
汪溪洁
XING Hongyan;ZHANG Yizhe;WANG Meiting;ZHAO Qi;WANG Xijie(National Shanghai Center for New Drug Safety Evaluation and Research,China State Institute of Pharmaceutical Industry,Shanghai 201210;Shanghai InnoStar Bio-Tech Co.,Ltd.,Shanghai 201210)
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2019年第8期834-841,共8页
Chinese Journal of Pharmaceuticals
基金
上海市科委“科技创新行动计划”项目(17140900700)
十三五重大专项(2018ZX09201017-008)
关键词
人诱导多能干细胞
心肌细胞
疾病模型
药物筛选
human induced pluripotent stem cell(hiPSC)
cardiomyocyte
disease model
drug screening
